LEXICON PHARMACEUTICALS, INC. 10-Q

Item 5. Other Information Insider Trading Arrangements During the three months ended June 30, 2025, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. 27 Item 6. Exhibits Exhibit No. Description 10.1 — 2017 Equity Incentive Plan , as amended (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated June 2, 2025 and incorporated by reference herein). 10.2 — 2017 Non-Employee Directors’ Equity Incentive Plan , as amended (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated June 2, 2025 and incorporated by reference herein). *31.1 — Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *31.2 — Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *32.1 — Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS — XBRL Instance Document 101.SCH — XBRL Taxonomy Extension Schema Document 101.CAL — XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF — XBRL Taxonomy Extension Definition Linkbase Document 101.LAB — XBRL Taxonomy Extension Label Linkbase Document 101.PRE — XBRL Taxonomy Extension Presentation Linkbase Document 104 — Cover Page Interactive Data File (embedded within the Inline XBRL document) _____________________ * Filed herewith. 28 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: August 6, 2025 By: /s/ Michael S. Exton Michael S. Exton, Ph.D. Chief Executive Officer Date: August 6, 2025 By: /s/ Scott M. Coiante Scott M. Coiante Senior Vice President and Chief Financial Officer 29